Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYCLONE 3: Abemaciclib + Abiraterone + Prednisone in High-Risk Metastatic Hormone-Sensitive Prostate Cancer
jRCT2031220101Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2022
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Abemaciclib + Abiraterone + Prednisone/Prednisolone with Placebo + Abiraterone + Prednisone/Prednisolone (2 arms). Primary endpoint: Radiographic Progression-Free Survival (rPFS) Assessed by Investigator. Started Jun 2022; status: active, not recruiting.
02
Drugs
abemaciclib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCT2031220101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220101.